- Home
- MRNA vs RPRX Comparison
MRNA vs RPRX Comparison
Compare MRNA & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNA
- RPRX
- Stock Information
- Founded
- MRNA 2010
- RPRX 1996
- Country
- MRNA United States
- RPRX United States
- Employees
- MRNA N/A
- RPRX N/A
- Industry
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- MRNA Health Care
- RPRX Health Care
- Exchange
- MRNA Nasdaq
- RPRX Nasdaq
- Market Cap
- MRNA 16.0B
- RPRX 14.2B
- IPO Year
- MRNA 2018
- RPRX 2020
- Fundamental
- Price
- MRNA $24.72
- RPRX $32.60
- Analyst Decision
- MRNA Hold
- RPRX Strong Buy
- Analyst Count
- MRNA 20
- RPRX 4
- Target Price
- MRNA $54.47
- RPRX $42.50
- AVG Volume (30 Days)
- MRNA 10.2M
- RPRX 5.5M
- Earning Date
- MRNA 05-01-2025
- RPRX 05-08-2025
- Dividend Yield
- MRNA N/A
- RPRX 2.71%
- EPS Growth
- MRNA N/A
- RPRX N/A
- EPS
- MRNA N/A
- RPRX 1.91
- Revenue
- MRNA $3,236,000,000.00
- RPRX $2,263,576,000.00
- Revenue This Year
- MRNA N/A
- RPRX $31.56
- Revenue Next Year
- MRNA $22.07
- RPRX $5.94
- P/E Ratio
- MRNA N/A
- RPRX $17.05
- Revenue Growth
- MRNA N/A
- RPRX N/A
- 52 Week Low
- MRNA $23.15
- RPRX $24.05
- 52 Week High
- MRNA $170.47
- RPRX $34.20
- Technical
- Relative Strength Index (RSI)
- MRNA 36.68
- RPRX 54.58
- Support Level
- MRNA $23.68
- RPRX $32.02
- Resistance Level
- MRNA $27.21
- RPRX $32.31
- Average True Range (ATR)
- MRNA 2.06
- RPRX 0.97
- MACD
- MRNA -0.03
- RPRX 0.12
- Stochastic Oscillator
- MRNA 26.98
- RPRX 97.84
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.